Author

Katie Marceau

Observed name: K. Marceau

Institution: HonorHealth

Observed institution: HonorHealth

OpenAlex ID: A5015854591

E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases

2018 · Hani M. Babiker, Sara A. Byron, et al. · Investigational New Drugs · 28

A phase II pilot trial of nivolumab (N) + albumin bound paclitaxel (AP) + paricalcitol (P) + cisplatin (C) + gemcitabine (G) (NAPPCG) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC).

2018 · Erkut Hasan Borazanci, Gayle S. Jameson, et al. · Journal of Clinical Oncology · 21

Abstract CT224: Pilot study in patients with advanced solid tumors to evaluate feasibility of ferumoxytol (FMX) as tumor imaging agent prior to MM-398, a nanoliposomal irinotecan (nal-IRI)

2014 · Ramesh K. Ramanathan, Ronald L. Korn, et al. · Cancer Research · 17

Abstract CT152: A Phase II pilot trial of nivolumab (N) + albumin bound paclitaxel (AP) + paricalcitol (P) + cisplatin (C) + gemcitabine (G) (NAPPCG) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC)

2019 · Erkut H. Borazanci, Gayle Jameson, et al. · Cancer Research · 9

261 Lesion characterization with ferumoxytol MRI in patients with advanced solid tumors and correlation with treatment response to MM-398, nanoliposomal irinotecan (nal-IRI)

2014 · R.K. Ramanathan, R.L. Korn, et al. · European Journal of Cancer · 7

Abstract CT152: A Phase II pilot trial of nivolumab (N) + albumin bound paclitaxel (AP) + paricalcitol (P) + cisplatin (C) + gemcitabine (G) (NAPPCG) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC)

2019 · Erkut H. Borazanci, Gayle Jameson, et al. · Clinical Trials · 1

Works count: 6

Citation count: 83

H-index: 5

I10-index: 3